Trade Names:Kineret- Solution 100 mg per 0.67 mL
Blocks the biologic activity of interleukin-1 (IL-1) by competitively inhibiting IL-1 binding to IL-1 type I receptor, which is expressed in a wide variety of organs and tissues.
Bioavailability is 95%; T max is 3 to 7 h.
The t ½ is 4 to 6 h.
Mean plasma Cl decreased 70% to 75% in those with Ccr less than 30 mL/min.
Reduction in signs and symptoms, and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients who have failed at least 1 disease-modifying antirheumatic drug.
Hypersensitivity to Escherichia coli -derived proteins, anakinra, or any component of product.
Subcutaneous 100 mg/day.Renal Function Impairment
Subcutaneous 100 mg every other day for severe renal function impairment (Ccr less than 30 mL/min).
Store prefilled syringes in refrigerator (36° to 46°F). Do not freeze or shake. Protect from light.
None well documented.
None well documented.
Nausea (8%); diarrhea (7%); abdominal pain (5%).
Injection-site reaction (71%).
Upper respiratory tract infection (14%).
Worsening of rheumatoid arthritis (19%); arthralgia, flu-like symptoms (6%); hypersensitivity, serious infections (eg, cellulitis, pneumonia, bone and joint [3%]).
MonitorDisease state activity
Document baseline disease state activity (eg, number of tender or swollen joints, pain, disability). Reassess periodically to document response to therapy.Neutrophil count
Ensure that neutrophil count is assessed prior to starting therapy, then monthly for 3 mo, and thereafter quarterly for a period of up to 1 yr.
Category B .
Safety and efficacy not established.
Use with caution because of higher rate of infection in this population.
Because anakinra is substantially excreted by the kidneys, risk of toxicity is increased in patients with renal function impairment.
Decreased neutrophil count may occur.
Serious infections may occur. Monitor patient for signs and symptoms of infection (eg, persistent fever, sore throat, cellulitis). Immediately report to health care provider if noted. Be prepared to discontinue therapy if a serious infection develops or is suspected.
Do not give live vaccines concomitantly.
Copyright © 2009 Wolters Kluwer Health.